OT Re: IOMI
Doc,
This looks pretty good. You have any thoughts on the significance?
-W
Iomai Vaccine Confers Statistically Significant Protection Against Travelers' Diarrhea in Phase 2 Study
Wednesday August 1, 6:45 am ET
- Interim Data from Field Study Also Shows Patch Vaccine Limits Severity, Shortens Duration of Travelers' Diarrhea -
- Conference Call Scheduled for 8:30 a.m. Eastern Today -
GAITHERSBURG, Md., Aug. 1 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI - News) today announced that its patch-based vaccine for enterotoxigenic E. coli (ETEC) bacteria conferred statistically significant protection from travelers' diarrhea as compared to placebo, particularly for more severe cases, according to interim data from a double-blind Phase 2 field study. Vaccinated travelers were 75 percent less likely to suffer moderate or severe diarrhea from any cause (p<0.01) and 84 percent less likely to be afflicted by severe diarrhea (p<0.05). No vaccine-related serious adverse events were reported.
In addition to the protective effects, investigators found that the frequency and duration of diarrhea in vaccinated subjects who did contract disease was significantly lower than in their unvaccinated peers.
"The results from this study strongly suggest that the use of Iomai's needle-free, patch-based vaccine can have a notable impact in reducing the chances of suffering from the ravages of travelers' diarrhea," said Herbert L. DuPont, M.D., professor and director of the Center for Infectious Diseases at The University of Texas School of Public Health and the principal investigator on the trial. "Right now, we are generally limited to administering antibiotics after the illness has begun. An effective, easy-to-use vaccine would be a vast improvement and have an immediate impact on travel medicine."
The Trek Phase 2 field study followed 170 subjects, 111 who received a placebo and 59 who received two doses of Iomai's patch-based vaccine before traveling to Mexico or Guatemala. These efficacy results were particularly notable as the trial was conducted largely to gather information on the logistics of conducting such a study in the field. The study was conducted in collaboration with researchers from the Johns Hopkins Bloomberg School of Public Health and the University of Texas School of Public Health. |
